Mid-Face Volume Study

        Interested in Participating?

        Please read through the following study inclusions and exclusions before submitting your information to ensure you qualify. 


        • Male or female, the participant must be 18 or older at the time of signing the ICF
        • Participants seeking soft tissue augmentation in the mid-face


        • Has experienced trauma to the face within 6 months before enrollment or has residual deficiencies, deformities, or scarring
        • Active or recurrent inflammation or infection in either eye
        •  Tendency to develop hypertrophic scarring and/or keloid scarring
        • Active autoimmune disease
        • Current cutaneous or mucosal inflammatory or infectious processes (eg, acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion, in the face
        • Fat injection or permanent facial implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere on the face
        •  Temporary dermal filler injections in the face within 24 months before enrollment, semi-permanent fillers, or permanent facial implants (eg, poly-L-lactic acid, CaHA polymethylmethacrylate) anywhere in the face within 36 months before enrollment
        • Had botulinum toxin treatment in the cheek area (including crow’s feet) within 6 months before enrollment
        •  Had mesotherapy or cosmetic facial procedures on the face within 6 months before enrollment. Examples of mesotherapy or cosmetic facial procedures are face-lift, laser, photomodulation, intense pulsed light, radio frequency dermabrasion, moderate or greater depth chemical peel, or other ablative procedures
        • Tattoos, piercings, facial hair, or scars on the face that would interfere with the visualization of the face for the effectiveness assessment
        •  Undergone a dental procedure within 6 weeks before treatment or plan to undergo a dental procedure (other than prophylaxis or dental fillings) during the course of the study
        •  History of an allergic reaction or significant sensitivity to constituents of the study
        • Females who are pregnant, planning a pregnancy, or nursing.